Overview

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Status:
Recruiting

Trial end date:
2025-10-31

Target enrollment:

Participant gender:

Summary

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Peking University People's Hospital

Treatments:

Atorvastatin
Medroxyprogesterone
Medroxyprogesterone Acetate